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Short Communication
Cancer, cardiovascular disease and diabetes mortality among
women with a history of endometrial cancer
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Among 7182 women with endometrial cancer in Scotland, standardised mortality ratios (and 95% confidence intervals (CI)) were
6.38 (5.74–7.15) for all cancers and 1.10 (1.00–1.22) for circulatory diseases as underlying cause of death and 2.81 (2.19–3.70) for
diabetes as underlying/contributory cause of death.
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Endometrial cancer (malignant neoplasm of the corpus uteri) is
one of the five most common cancers among women and develops
in approximately 400 women in Scotland (ISD Scotland, 2004),
40 000 women in the United States (National Cancer Institute,
2006) and 77 000 women across Europe each year (International
Agency for Research on Cancer, 2005). Age-standardised incidence
of endometrial cancer in Scotland has increased over the last
decade and mortality rates appear stable (ISD Scotland, 2004).
Compared with many other cancers, the survival after a diagnosis
of endometrial cancer is high, with survival relative to the age-
matched general population of women of approximately 70%, five
years after diagnosis (Harris et al, 1998; Quinn et al, 2001). It is
therefore important to consider the role of other causes of
morbidity and mortality among women with endometrial cancer.
Endometrial cancer is associated with factors that increase
(including obesity, diabetes and hypertension) (Shoff and
Newcomb, 1998; Parazzini et al, 1999; Anderson et al, 2001; Xu
et al, 2005, 2006; Trentham-Dietz et al, 2006) and decrease
(including higher socio-economic status and not smoking) (Kelsey
et al, 1982) risk of cardiovascular disease. In addition, there is an
association with polycystic ovary syndrome (Hardiman et al,
2003), the effect on cardiovascular disease of which is unclear. It is
plausible that women who survive endometrial cancer may be at
high risk of cardiovascular disease and could benefit from effective
approaches to primary and secondary prevention.
In Scotland, linkage between several centrally held datasets
including cancer registries and death records is performed using
probability matching (Kendrick and Clarke, 1993), which uses all
available identifying information, including name, date of birth,
postal code and patient reference number, to link records
belonging to the same person.
We examined the causes of death among women with
endometrial cancer and compared mortality from all causes, all
cancers and selected major cancers, all diseases of the circulatory
system (specifically ischaemic heart disease and stroke) and
diabetes between women with endometrial cancer and women in
the general population of Scotland.
MATERIALS AND METHODS
The Information Services Division of National Health Service
National Services Scotland identified a retrospective cohort of
women in Scotland who received a registration of malignant
neoplasm of the corpus uteri (ninth and tenth revisions of the
International Classification of Diseases (ICD-9 and ICD-10) codes
182 and C54) between 1981 and 2000 and provided anonymised
data linked to mortality records for cohort members.
Cause of death in Scotland was coded using ICD-9 codes for
deaths between 1981 and 1999 and ICD-10 codes for deaths
occurring after 1999. An area-based measures of deprivation
category was used as a marker for socio-economic status, which is
a potentially important confounding factor. The Carstairs Index is
derived from four census indicators: low social class, lack of car
ownership, overcrowding and male unemployment for postal
sectors derived from 1981 and 1991 census data (Carstairs and
Morris, 1991).
Estimates of the numbers of women in Scotland by age group (in
5-year groups from 30 to 34 and 85þ ), calendar period (1981–
1985, 1986–1990, 1991–1996, 1997–2002) and deprivation cate-
gory were derived from the Registrar General for Scotland mid-
year population estimates and 1981 and 1991 census population
estimates. The number of deaths for the general population of
women in Scotland by 5-year age group, calendar period and
deprivation category were available for all causes combined and
for selected underlying causes of death: all cancers (ICD-9: 140–
208, ICD-10: C0-C97), breast cancer (ICD-9: 174, ICD-10: C50),
ovarian cancer (ICD-9: 183, ICD-10: C56), colon cancer (ICD-9:
153, ICD-10: C18), all diseases of the circulatory system (ICD-9:
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390– 459, ICD-10: I00-I99), ischaemic heart disease (ICD-9: 410–
414, ICD-10: I20-I25), cerebrovascular disease (ICD-9: 430–438,
ICD-10: I60-I69, G45). Diabetes (ICD-9: 250, ICD-10: E10-E14) was
considered as either an underlying or contributory cause of death.
For each cohort member, date of endometrial cancer diagnosis
was grouped into calendar periods of 1981–1985, 1986–1990,
1991– 1995 and 1996– 2000. Length of follow-up was calculated in
days either between diagnosis and death or between diagnosis and
the end of 2002 for survivors. Calendar periods at death were
grouped in the following categories: 1981–1985, 1986–1990,
1991– 1996 and 1997–2002. The analysis was based on women of
30 years and older at diagnosis who had complete data available on
age, deprivation category and date of diagnosis.
Standardised mortality ratios (SMRs) for all combined and
selected causes of death were derived for the endometrial cancer
cohort using indirect standardisation. Age group, calendar period
and deprivation category-specific mortality rates for the whole
population of women in Scotland over 29 years of age
(approximately 1.7 million women) were used as the standard.
CIs were estimated using the Fieller method, which takes account
of potential errors in expected death rates (Silcocks, 1994).
RESULTS
The cohort included 16 women below 30 years of age and four
women with missing data for deprivation category and these 20
women were excluded, leaving 7182 women in the analysis. The
mean and median age at diagnosis of endometrial cancer was 65
years. Median time between diagnosis of endometrial cancer and
death or the end of the follow-up period at 31 December 2002 for
the cohort was 5.0 years (inter-quartile range: 1.8–10.5 years).
Approximately half of the cohort (3615 women) died during the
follow-up period and five year absolute survival was 62%. The
single largest cause of death was endometrial cancer with 1529
(42%) death certificates giving endometrial cancer (ICD-9 and
ICD-10 codes 182 and C54) as the underlying cause of death. There
were another 210 (5.8%) death certificates that gave ICD-9 and
ICD-10 codes 179 and C55 (uterus, part unspecified) for the
underlying cause of death. A further 384 death certificates (11%)
included endometrial cancer (ICD-9 and ICD-10 codes 182 and
C54) as a contributory cause of death.
Breast cancer, ovarian cancer, ischaemic heart disease and
cerebrovascular disease were identified as the underlying cause
of death for 114 (3.2%), 87(2.4%), 394 (11%), 238 (6.6%) deaths,
respectively. Diabetes was reported as either underlying or
contributory cause of death on 220 death certificates (6.1%).
Diabetes was given as the underlying cause of death on only 32
death certificates. The most common underlying causes of death
when diabetes was given as a contributory cause were ischaemic
heart disease (52 deaths), endometrial cancer (29 deaths) and
cerebrovascular disease (24 deaths). Table 1 shows SMRs for all
causes, all cancers, endometrial, breast and ovarian cancer, all
circulatory diseases, ischaemic heart disease, cerebrovascular disease
and diabetes among the cohort of women with endometrial cancer.
DISCUSSION
In this first cohort study of mortality in Britain among women with
endometrial cancer we found that over 42% of death certificates
included endometrial cancer as the underlying cause of death. We
found that in the cohort, ovarian cancer mortality was over four
times higher and all-cause, breast cancer and diabetes-related
mortality was approximately twice as high as that of the general
female population, after allowing for potential differences in
distribution of age, calendar period and deprivation category
between groups. In contrast, mortality from ischaemic heart
disease and cerebrovascular disease were similar in the cohort and
the general female population.
A similar proportion of deaths ascribed to endometrial cancer
was also reported by a smaller study in Iowa in which 39 out of 93
death certificates for women with a history of endometrial cancer
gave endometrial cancer as the underlying cause of death (Folsom
et al, 2004). The high breast cancer mortality in the endometrial
cancer cohort reflects shared risk factors (including low parity, late
menopause, high socio-economic status and obesity) but perhaps
also the increased endometrial cancer risk associated with
tamoxifen treatment for breast cancer (Bergman et al, 2000).
Tamoxifen treatment appears to be associated with a reduced risk
of cardiovascular disease (Swerdlow and Jones, 2005). We were
unable to determine in our study the temporal relationship
between endometrial and breast cancers. Higher ovarian cancer
mortality in the cohort may again be related to shared risk factors
as for breast cancer, but could also be potentially related to
oestrogen production by some ovarian cancers.
Recording of diabetes on death certificates is known to be
incomplete (Thomason et al, 2005). Under-reporting of diabetes
on death certificates appears to be even more marked for people
who died of cancer than among those with other recorded causes
of death (McEwen et al, 2006). This would suggest a bias that may
underestimate excess diabetes-related mortality among women
with endometrial cancer.
The relative risk of coronary heart disease among women with
diabetes is approximately 2.5-fold that of women without diabetes
(Lee et al, 2000). The presumed higher prevalence of diabetes
among women with endometrial cancer could therefore be expected
to be associated with an increase in cardiovascular disease
mortality. A long-term follow-up study of women with polycystic
ovary syndrome also reported no excess of cardiovascular disease
mortality, despite an excess of prevalence of and mortality from
diabetes (Wild et al, 2000). The absence of excess cardiovascular
Table 1 Numbers of deaths, mortality ratios (SMR) and 95% CI for selected causes of death between 1981 and 2002 among women with endometrial
cancer diagnosed between 1981 and 2000 in Scotland, standardised for age, deprivation category and calendar period
Cause of death (ICD codes) Deaths SMR 95% CI
All causes 3615 2.34 2.21–2.49
All cancers (ICD-9: 140–208, ICD-10: C0–C97) 2357 6.38 5.74–7.15
Endometrial cancer (ICD-9: 182, ICD-10: C54) 1529 277 150–1682
Breast cancer (ICD-9: 174, ICD-10: C50) 114 2.05 1.51–2.90
Ovarian cancer (ICD-9: 183, ICD-10: C56) 87 4.26 2.77–7.74
All circulatory disease (ICD-9: 390–459, ICD-10: I00– I99) 795 1.10 1.00–1.22
Ischaemic heart disease (ICD-9: 410–414, ICD-10: I20– I25) 394 1.10 0.96–1.27
Cerebrovascular disease (ICD-9: 430–438, ICD-10: I60– I69, G45) 238 1.02 0.85–1.22
Diabetes (underlying or contributory cause) (ICD-9: 250, ICD-10: E10–E14) 220 2.81 2.19–3.70
Abbreviations: CI, confidence intervals; SMR, standardized mortality ratios.
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disease mortality in the cohort could potentially be explained by a
combination of endometrial and breast cancer acting as competing
causes of death, residual confounding, non-random misclassifica-
tion bias or possibly a protective effect of exposure to unopposed
oestrogen against cardiovascular disease. A prospective cohort
study is required to establish the role of these factors.
The use of routine data means that the potential confounding
effects of only age, calendar period and deprivation category could
be addressed in this study. We were unable to consider the effects
of other potential confounding factors including parity, body mass
index, fat distribution, smoking habit, presence and treatment for
hypertension or dyslipidaemia and use of hormone replacement
therapy, aspirin, anti-hypertensives, lipid-lowering drugs or
tamoxifen.
There is the potential for errors in record linkage, but this is
unlikely to have a marked effect as the linkage process is estimated
to be 98% accurate (Harley and Jones, 1999). The codes and the
rules for coding the underlying cause of death changed with the
introduction of ICD-10 codes for mortality data in 2000 and we
have assumed that any effect of this would be similar for women
with and without endometrial cancer.
In conclusion, we have shown that endometrial cancer is
associated with an approximately fourfold increase in ovarian
cancer mortality and a twofold increase in mortality from breast
cancer and diabetes, and that cardiovascular disease mortality
among women with a history of endometrial cancer is similar to
that observed in the general population. The findings suggest that
women with endometrial cancer should receive similar advice on
lifestyle and pharmacological treatment for primary and secondary
prevention of cardiovascular disease to women in the general
population. The high diabetes prevalence and mortality among
women with endometrial cancer suggests that weight control and
regular physical activity are particularly important for this group
of women. Further research is required to establish the temporal
relationships between endometrial cancer, ovarian cancer, breast
cancer and diabetes and to establish appropriate approaches to
screening for and management of each condition among women
with one or more of the other conditions.
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